Advances in the Treatment of Higher-Risk MDS: Current Strategies and Emerging Therapies
Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, dysplasia of blood and bone marrow cells, and an elevated risk of progression to acute myeloid leukemia (AML). Patients with higher-risk MDS have a poore...
Saved in:
Main Author: | Stefani Parmentier |
---|---|
Format: | Article |
Language: | English |
Published: |
THE HEALTHBOOK COMPANY LTD.
2025-06-01
|
Series: | healthbook TIMES. Oncology Hematology |
Online Access: | https://doi.org/10.36000/HBT.OH.2025.24.182 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Projective MDS Codes Over GF(27)
by: Emad Bakr Abdulkareem Al-Zangana
Published: (2021-06-01) -
MDS DIAGNOSIS? STILL BY BONE MARROW EXAMINATION?
by: Moshe Mittelman
Published: (2025-07-01) -
Myelodysplastic Neoplasms (MDS): Pathogenesis and Therapeutic Prospects
by: Xuefeng Li, et al.
Published: (2025-05-01) -
A Multi-Well Method for the CD138 and AML/MDS FISH Testing of Multiple Biomarkers on a Single Slide in Multiple Myeloma and AML/MDS Patients
by: Frank Tambini, et al.
Published: (2025-06-01) -
Current and emerging treatment strategies for Duchenne muscular dystrophy
by: Mah J
Published: (2016-07-01)